{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:47:44Z","timestamp":1759333664888,"version":"build-2065373602"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jaad.2022.07.062","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T23:41:08Z","timestamp":1685576468000},"page":"1243-1255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunotherapy for keratinocyte cancers. Part II: Identification and management of cutaneous side effects of immunotherapy treatments"],"prefix":"10.1016","volume":"88","author":[{"given":"Anne Lynn S.","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Zaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernice Y.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jaad.2022.07.062_bib1","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/cncr.32802","article-title":"Annual report to the nation on the status of cancer, part I: national cancer statistics","volume":"126","author":"Henley","year":"2020","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jaad.2022.07.062_bib2","doi-asserted-by":"crossref","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2022.07.062_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/jdv.17402","article-title":"Management of immune-related adverse events in anti-PD-1-treated patients with advanced cutaneous squamous cell carcinoma","volume":"36","author":"Gambichler","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2022.07.062_bib4","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0190-9622(99)70261-6","article-title":"Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream","volume":"41","author":"Beutner","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2022.07.062_bib5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1067\/mjd.2001.113689","article-title":"Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial","volume":"44","author":"Marks","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2022.07.062_bib6","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1365-2133.2005.06486.x","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe","volume":"152","author":"Schulze","year":"2005","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2022.07.062_bib7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/039463201102400225","article-title":"Exaggerated imiquimod application site reactions in the context of systemic tumor necrosis factor-alpha inhibition: more than a coincidental occurrence?","volume":"24","author":"Saggini","year":"2011","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"7","key":"10.1016\/j.jaad.2022.07.062_bib8","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/ijd.14744","article-title":"Treatment of erosive pustular dermatosis: a systematic review of the literature","volume":"59","author":"Lee","year":"2020","journal-title":"Int J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2022.07.062_bib9","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/archdermatol.2009.278","article-title":"Erosive pustular dermatosis of the scalp following treatment with topical imiquimod for actinic keratosis","volume":"145","author":"Vaccaro","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2022.07.062_bib10","first-page":"828749","article-title":"Erosive pustular dermatosis of the scalp induced by imiquimod","volume":"2012","author":"Corradin","year":"2012","journal-title":"Case Rep Dermatol Med"},{"issue":"1","key":"10.1016\/j.jaad.2022.07.062_bib11","doi-asserted-by":"crossref","first-page":"e12770","DOI":"10.1111\/dth.12770","article-title":"Two cases of erosive pustular dermatosis of the scalp occurring after topical 3.75% imiquimod for actinic keratoses","volume":"32","author":"Giuffrida","year":"2019","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2022.07.062_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1440-0960.2004.00030.x","article-title":"Psoriasis induced by topical imiquimod","volume":"45","author":"Wu","year":"2004","journal-title":"Australas J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2022.07.062_bib13","first-page":"346","article-title":"Lupus erythematosus-like imiquimod reaction: a diagnostic pitfall","volume":"38","author":"Barr","year":"2011","journal-title":"J Cutan Pathol"},{"issue":"1","key":"10.1016\/j.jaad.2022.07.062_bib14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1440-0960.2010.00676.x","article-title":"Eruptive keratoacanthoma and squamous cell carcinoma complicating imiquimod therapy: response to oral acitretin","volume":"52","author":"Foxton","year":"2011","journal-title":"Australas J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2022.07.062_bib15","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/DSS.0000000000002739","article-title":"Complete and sustained remission of metastatic cutaneous squamous cell carcinoma in a liver transplant patient treated with talimogene laherparepvec","volume":"47","author":"Nguyen","year":"2021","journal-title":"Dermatol Surg"},{"issue":"15","key":"10.1016\/j.jaad.2022.07.062_bib16","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-10-0196","article-title":"Phase I\/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III\/IV squamous cell cancer of the head and neck","volume":"16","author":"Harrington","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.jaad.2022.07.062_bib18","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/cup.14094","article-title":"Talimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma","volume":"48","author":"Henning","year":"2021","journal-title":"J Cutan Pathol"},{"issue":"4","key":"10.1016\/j.jaad.2022.07.062_bib19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1001\/jamadermatol.2018.5347","article-title":"Extensive pigment incontinence mimicking persistent melanoma after talimogene laherparepvec therapy","volume":"155","author":"Danesh","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2022.07.062_bib20","unstructured":"See clinicaltrials.gov for study identifier NCT 02978625. Accessed September 14, 2022. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02978625?term=02978625&draw=2&rank=1"},{"issue":"4","key":"10.1016\/j.jaad.2022.07.062_bib21","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jaad.2021.03.024","article-title":"Prognostic significance of cutaneous immune-related adverse events in patients with melanoma and other cancers on immune checkpoint inhibitors","volume":"86","author":"Thompson","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2022.07.062_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2022.07.062_bib23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2022.07.062_bib24","doi-asserted-by":"crossref","first-page":"e000775","DOI":"10.1136\/jitc-2020-000775","article-title":"Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing","volume":"8","author":"Rischin","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.jaad.2022.07.062_bib25","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2022.07.062_bib26","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","article-title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial","volume":"22","author":"Stratigos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jaad.2022.07.062_bib27","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jaad.2018.08.017","article-title":"Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study","volume":"80","author":"Chang","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2022.07.062_bib28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejca.2021.08.018","article-title":"Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma","volume":"157","author":"Baggi","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.jaad.2022.07.062_bib29","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/bjd.20569","article-title":"Cemiplimab-rwlc in advanced cutaneous squamous cell carcinoma: real-world experience in a French dermatology department","volume":"185","author":"Guillaume","year":"2021","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2022.07.062_bib30","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jgo.2021.02.026","article-title":"Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma","volume":"12","author":"Valentin","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jaad.2022.07.062_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2020.07.029","article-title":"Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study","volume":"138","author":"Salzmann","year":"2020","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.jaad.2022.07.062_bib32","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jamadermatol.2022.0354","article-title":"Risk factors for the development of bullous pemphigoid in US patients receiving immune checkpoint inhibitors","volume":"158","author":"Said","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2022.07.062_bib33","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.jaad.2022.07.062_bib34","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamadermatol.2021.0326","article-title":"Patterns of cutaneous and noncutaneous immune-related adverse events among patients with advanced cancer","volume":"157","author":"Thompson","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2022.07.062_bib35","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1-PD-L1 inhibitor therapy and association with multiple oncologic outcomes","volume":"79","author":"Lee","year":"2018","journal-title":"JAAD"},{"issue":"6","key":"10.1016\/j.jaad.2022.07.062_bib36","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1111\/jdv.17940","article-title":"Successful treatment of eruptive keratoacanthomas with actitretin for patients on checkpoint inhibitor immunotherapy","volume":"36","author":"Schwartz","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.jaad.2022.07.062_bib37","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/jamadermatol.2017.0989","article-title":"Eruptive keratoacanthomas associated with pembrolizumab therapy","volume":"153","author":"Freites-Martinez","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2022.07.062_bib38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/dermatopathology9010010","article-title":"Bullous pemphigoid in patients receiving immune-checkpoint inhibitors and psoriatic patients- focus on clinical and histopathological variation","volume":"9","author":"Niebel","year":"2022","journal-title":"Dermatopathology (Basel)"},{"issue":"8","key":"10.1016\/j.jaad.2022.07.062_bib39","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1111\/jdv.17253","article-title":"Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1\/PD-L1 therapy: A national retrospective study","volume":"35","author":"Juzot","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2022.07.062_bib40","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jaad.2021.11.050","article-title":"Histologic subtype of cutaneous immune-related adverse events predicts overall survival in patients receiving immune checkpoint inhibitors","volume":"87","author":"Hirotsu","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2022.07.062_bib41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2022.07.062_bib42","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/bjd.20074","article-title":"Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity","volume":"185","author":"Thompson","year":"2021","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2022.07.062_bib43","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"36","key":"10.1016\/j.jaad.2022.07.062_bib44","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jaad.2022.07.062_bib45","first-page":"6119","article-title":"Multinational association of supportive care in cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors","volume":"28","author":"Choi","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2022.07.062_bib47","first-page":"100506","article-title":"A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution","volume":"30","author":"Masterson","year":"2022","journal-title":"Cancer Treat Res Commun"},{"issue":"3","key":"10.1016\/j.jaad.2022.07.062_bib48","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1634\/theoncologist.2018-0531","article-title":"Resolution of pembrolizumab-associated steroid-refractory lichenoid dermatitis with cyclosporine","volume":"24","author":"Fixsen","year":"2019","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.jaad.2022.07.062_bib49","first-page":"6","article-title":"Steroid-refractory lichenoid eruption associated with pembrolizumab in a patient with non-small cell lung cancer","volume":"2","author":"Kou","year":"2021","journal-title":"HCA Healthc J Med"},{"issue":"3","key":"10.1016\/j.jaad.2022.07.062_bib50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jdcr.2020.01.008","article-title":"Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma","volume":"6","author":"Virgen","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"9","key":"10.1016\/j.jaad.2022.07.062_bib51","article-title":"Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature","volume":"27","author":"Klepper","year":"2021","journal-title":"Dermatol Online J"},{"issue":"6","key":"10.1016\/j.jaad.2022.07.062_bib52","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2326-6066.CIR-18-0682","article-title":"IL17A blockade\u00a0successfully treated psoriasiform dermatologic toxicity from immunotherapy","volume":"7","author":"Johnson","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jaad.2022.07.062_bib53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jdcr.2021.03.029","article-title":"Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma","volume":"11","author":"Glinos","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.jaad.2022.07.062_bib54","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jaad.2022.02.030","article-title":"Treatment of immune checkpoint inhibitor-mediated psoriasis: A systematic review","volume":"87","author":"Said","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2022.07.062_bib55","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaad.2020.08.137","article-title":"Immune checkpoint-mediated psoriasis: a multicenter European study of 115 patients from the European Network for cutaneous adverse event to oncologic drugs (ENCADO) group","volume":"84","author":"Nikolaou","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"30","key":"10.1016\/j.jaad.2022.07.062_bib56","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment Outcomes of Immune-Related Cutaneous Adverse Events","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2022.07.062_bib57","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/bjd.19129","article-title":"Treatment of severe cutaneous adverse reaction with tocilizumab","volume":"183","author":"Hibler","year":"2020","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2022.07.062_bib58","doi-asserted-by":"crossref","first-page":"e000604","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge patients with\u00a0immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and\u00a0suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222202607X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222202607X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:25:11Z","timestamp":1759274711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222202607X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S019096222202607X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2022.07.062","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy for keratinocyte cancers. Part II: Identification and management of cutaneous side effects of immunotherapy treatments","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.07.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.06.1206","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(23)00645-X","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}